Ken Griffin Vertex Pharmaceuticals Inc Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 209,500 shares of VRTX stock, worth $85.5 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
209,500
Previous 135,400
54.73%
Holding current value
$85.5 Million
Previous $63.5 Million
53.53%
% of portfolio
0.02%
Previous 0.01%
Shares
27 transactions
Others Institutions Holding VRTX
# of Institutions
1,724Shares Held
221MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$10.9 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$9.45 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.7 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.82 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$3.67 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $105B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...